These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27348588)

  • 1. Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
    Lauriol J; Cabrera JR; Roy A; Keith K; Hough SM; Damilano F; Wang B; Segarra GC; Flessa ME; Miller LE; Das S; Bronson R; Lee KH; Kontaridis MI
    J Clin Invest; 2016 Aug; 126(8):2989-3005. PubMed ID: 27348588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.
    Yi JS; Perla S; Enyenihi L; Bennett AM
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.
    Roy R; Krenz M
    J Mol Cell Cardiol; 2017 Nov; 112():83-90. PubMed ID: 28911943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
    Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
    PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
    Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
    Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.
    Clay SA; Domeier TL; Hanft LM; McDonald KS; Krenz M
    Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1086-95. PubMed ID: 25724491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose dasatinib rescues cardiac function in Noonan syndrome.
    Yi JS; Huang Y; Kwaczala AT; Kuo IY; Ehrlich BE; Campbell SG; Giordano FJ; Bennett AM
    JCI Insight; 2016 Dec; 1(20):e90220. PubMed ID: 27942593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
    Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
    Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital sensorineural hearing loss as the initial presentation of
    Gao X; Huang SS; Qiu SW; Su Y; Wang WQ; Xu HY; Xu JC; Kang DY; Dai P; Yuan YY
    J Med Genet; 2021 Jul; 58(7):465-474. PubMed ID: 32737134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
    Edwards MA; Crombie K; Schramm C; Krenz M
    J Appl Physiol (1985); 2015 Jan; 118(1):124-31. PubMed ID: 25359717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
    Schramm C; Edwards MA; Krenz M
    J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome.
    Krenz M; Gulick J; Osinska HE; Colbert MC; Molkentin JD; Robbins J
    Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18930-5. PubMed ID: 19017799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions.
    Bellio M; Garcia C; Edouard T; Voisin S; Neel BG; Cabou C; Valet P; Mori J; Mazharian A; Senis YA; Yart A; Payrastre B; Severin S
    Blood; 2019 Dec; 134(25):2304-2317. PubMed ID: 31562133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
    Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
    Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines.
    Yi JS; Perla S; Huang Y; Mizuno K; Giordano FJ; Vinks AA; Bennett AM
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):589-604. PubMed ID: 33689087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation.
    Araki T; Chan G; Newbigging S; Morikawa L; Bronson RT; Neel BG
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4736-41. PubMed ID: 19251646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
    Kontaridis MI; Yang W; Bence KK; Cullen D; Wang B; Bodyak N; Ke Q; Hinek A; Kang PM; Liao R; Neel BG
    Circulation; 2008 Mar; 117(11):1423-35. PubMed ID: 18316486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SHP2 sails from physiology to pathology.
    Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
    Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
    Lorca R; Pannone L; Cuesta-Llavona E; Bocchinfuso G; Rodríguez-Reguero J; Carpentieri G; Hernando I; Flex E; Tartaglia M; Coto E; Gómez J; Martinelli S
    Clin Genet; 2021 Mar; 99(3):457-461. PubMed ID: 33354767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
    Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
    Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.